slide1 n.
Download
Skip this Video
Download Presentation
Francisco Viegas Neves da Silva ¹ ; Ronaldo Hallal² and André Guimarães ²

Loading in 2 Seconds...

play fullscreen
1 / 13

Francisco Viegas Neves da Silva ¹ ; Ronaldo Hallal² and André Guimarães ² - PowerPoint PPT Presentation


  • 74 Views
  • Uploaded on

Compulsory License and Access to Medicines: Economics Savings of Efavirenz in Brazil. Francisco Viegas Neves da Silva ¹ ; Ronaldo Hallal² and André Guimarães ² International Cooperation Unit ¹ Care and Quality of Life Unit ² Department of STD, AIDS and VH Secretariat for Health Surveillance

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Francisco Viegas Neves da Silva ¹ ; Ronaldo Hallal² and André Guimarães ²' - jakeem-reid


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Compulsory License and Access to Medicines: Economics Savings of Efavirenz in Brazil

Francisco Viegas Neves da Silva¹;

Ronaldo Hallal² and André Guimarães²

International Cooperation Unit¹

Care and Quality of Life Unit²

Department of STD, AIDS and VH

Secretariat for Health Surveillance

Ministry of Health

XIX – International AIDS Conference (Washington - July/2012)

brazilian health system
Brazilian Health System

1988’s Constitution – “Health is a citizens right and a duty of the State”

Universal Access to ARV Law issued in 1996

Strong participation of Civil Society in the National HIV response

Industrial Property Law 1996

efavirenz background
Efavirenz background

Patented in Brazil in 1996. (PP1100250-6 and PI9608839-7). Main patent expires in August/2012. (pipeline)

75 thousand patients on EFV in 2007.

In 2007, after more than 8 price negotiation meetings the patent owner initially offered a price of US$1.59 per pill at the end offered a price reduction of 30% (US$1.11 per pill).

At the same time the patent owner was supplying EFV to Thailand at the cost of US$ 0.65 per pill.

Brazil considered this unacceptable.

slide4
Ordinance 886 of the MOH of Brazil (24/april/2007) – public interest.

Presidential Decree nº 6.108 (04/may/2007)

–”compulsory license, on the ground of public interest, of Efavirenz’s patents, for public non-commercial use”

- Duration: 5 years, allowing extension for equal period

- Royaltiy fee for the patent owner (1,5% on the cost of the finished product)

- Patent owner obligated to transfer knowledge and information necessary to reproduce the patented medicine

Renewal of CL by the Decree nº. 7723 (04/may/2012)

Compulsory License legal framework

what is a compulsory license
Compulsory licensing is when a government allows someone else to produce the patented product or process without the consent of the patent owner. A royalty fee is paid to compensate the patent owner. It is one of the flexibilities on patent protection included in the WTO’s agreement on intellectual property — the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement.

(Source: World Trade Organization)

What is a compulsory license?
slide6

National production

CL

Effects of the Compulsory License

evolution of prices efv 600mg
Evolution of prices EFV 600mg

CL

National production

slide9
EFV 200mg annual cost per patient

1999 = US$2,544 (inclusion)

2007 = US$259 (after CL)

2012 = US$107 (international suppliers)

EFV 600mg annual cost per patient

2003 = US$772 (inclusion)

2007 = US$158.78 (after CL)

2009 = US$279 (national production)

2011 = US$294

Explanation

conclusion
Conclusion

Total savings from 2007-2011 with the Compulsory License was around US$ 103,600,000. (includes savings of EFV 200mg)

With the Compulsory License Brazil has saved 58,47% buying from generic suppliers.

slide12
International prices are still lower than the ones offered to Brazil;

Intellectual property is a significant element of price negotiation;

It is necessary the full use and implementation of TRIPS flexibilities such as Compulsory Licenses to increase access to medicines.

Brazil has shown that increasing access is more important than economics.

Challenges and conclusion

slide13
Obrigado!

Thank you very much!

francisco.viegas@aids.gov.br

ad